ライフサイエンスコーパス: brentuximab vedotin

1 ., a CD30-positive expression for the use of brentuximab vedotin).

2 consistent with the known safety profile of brentuximab vedotin.

3 e enrolled and received at least one dose of brentuximab vedotin.

4 e development of the antibody-drug-conjugate brentuximab vedotin.

5 andomly assigned to pembrolizumab and 153 to brentuximab vedotin.

6 en with ALK+ ALCL were enrolled and received brentuximab vedotin.

7 zumab and 16 (11%) of 152 patients receiving brentuximab vedotin.

8 17, a total of 12 patients with LyP received brentuximab vedotin.

9 ther anticancer therapy after treatment with brentuximab vedotin.

10 oth autologous stem-cell transplantation and brentuximab vedotin.

11 isease progressed on or after treatment with brentuximab vedotin.

12 ter autologous stem-cell transplantation and brentuximab vedotin.

13 78% after a relapse following the receipt of brentuximab vedotin.

14 ational design of combination therapies with brentuximab vedotin.

15 nivolumab group fixed nivolumab 3 mg/kg with brentuximab vedotin 1.2 mg/kg (cohort D) or 1.8 mg/kg (c

16 ivolumab 3 mg/kg and ipilimumab 1 mg/kg with brentuximab vedotin 1.2 mg/kg (cohort G) or 1.8 mg/kg (c

17 o 5 of each cycle orally, followed by either brentuximab vedotin 1.8 mg/kg and a placebo form of vinc

18 A total of 102 patients were treated with brentuximab vedotin 1.8 mg/kg by intravenous infusion ev

19 Intravenous brentuximab vedotin 1.8 mg/kg infused over 30 minutes ev

20 izumab 200 mg intravenously every 3 weeks or brentuximab vedotin 1.8 mg/kg intravenously every 3 week

21 d web response system to receive intravenous brentuximab vedotin 1.8 mg/kg once every 3 weeks, for up

22 Brentuximab vedotin 1.8 mg/kg was administered every 3 w

23 f six cohorts: in the ipilimumab group fixed brentuximab vedotin 1.8 mg/kg with ipilimumab 1 mg/kg (c

24 Enrolled patients received brentuximab vedotin (1.8 mg/kg) and nivolumab (3 mg/kg)

25 00% CD30 expression levels were treated with brentuximab vedotin (1.8 mg/kg) every 3 weeks for a maxi

26 re randomly assigned (1:1) to receive A+AVD (brentuximab vedotin, 1.2 mg/kg of bodyweight, doxorubici

27 After brentuximab vedotin, 12 patients (27%, 95% CI 13-40) wer

28 Clinical activity and safety of brentuximab vedotin, a CD30 targeting antibody-drug conj

29 In the present investigation, we evaluated brentuximab vedotin, a CD30-directed Ab-drug conjugate,

30 r study evaluated the efficacy and safety of brentuximab vedotin, a CD30-directed antibody-drug conju

31 l study evaluated the efficacy and safety of brentuximab vedotin, a CD30-directed antibody-drug conju

32 Recently, brentuximab vedotin, a conjugate of an anti-CD30 antibod

33 Brentuximab vedotin, a monoclonal antibody (cAC10) conju

34 s lymphoma patients treated with single-dose brentuximab vedotin, a new anti-CD30 monoclonal antibody

35 ith R/R HL who obtained CR with single-agent brentuximab vedotin achieved long-term disease control a

36 es had been taken into account in developing brentuximab vedotin (Adcetris), an ADC that recently rec

37 l study evaluated the safety and activity of brentuximab vedotin administered sequentially with CHOP

38 Brentuximab vedotin, administered sequentially with CHOP

39 Intravenous brentuximab vedotin administration approximately every 3

40 Early consolidation with brentuximab vedotin after autologous stem-cell transplan

41 reatment after A+CHP and 50% with subsequent brentuximab vedotin after CHOP.

42 tion of patients who were PET-negative after brentuximab vedotin alone or brentuximab vedotin followe

43 y well tolerated and had activity similar to brentuximab vedotin alone.

44 , open-label study evaluated the efficacy of brentuximab vedotin, an anti-CD30 antibody-drug conjugat

45 Brentuximab vedotin, an effective anti-CD30 antibody-dru

46 lled and randomly assigned to a group (66 to brentuximab vedotin and 65 to physician's choice), with

47 d phase 2 dose was deemed to be 1.8 mg/kg of brentuximab vedotin and 90 mg/m(2) of bendamustine, whic

48 21 (95%) of 22 patients given brentuximab vedotin and ABVD achieved complete remission

49 ured in 41% of all patients (14 [56%] in the brentuximab vedotin and ABVD group and seven [27%] in th

50 ntuximab vedotin and AVD group), and, in the brentuximab vedotin and ABVD group only, pulmonary toxic

51 neutropenia (20 [80%] of 25 patients in the brentuximab vedotin and ABVD group vs 20 [77%] of 26 pat

52 were febrile neutropenia (four [16%] in the brentuximab vedotin and ABVD group vs two [8%] in the br

53 r, an unacceptable number of patients in the brentuximab vedotin and ABVD groups had pulmonary toxic

54 The recent approval of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, for c

55 ABVD group vs 20 [77%] of 26 patients in the brentuximab vedotin and AVD group), anaemia (five [20%]

56 ab vedotin and ABVD group vs two [8%] in the brentuximab vedotin and AVD group), and, in the brentuxi

57 edotin and ABVD group and seven [27%] in the brentuximab vedotin and AVD group).

58 ission, as did 24 (96%) of 25 patients given brentuximab vedotin and AVD.

59 d that replacing vinblastine with nivolumab (brentuximab vedotin and nivolumab [AN] + doxorubicin and

60 Brentuximab vedotin and nivolumab exhibit activity in pa

61 aimed to evaluate the safety and efficacy of brentuximab vedotin and nivolumab in untreated older pat

62 All drugs were given intravenously; brentuximab vedotin and nivolumab were given every 3 wee

63 homas have durable responses to single-agent brentuximab vedotin and show longer progression-free sur

64 trials are assessing novel agents, including brentuximab vedotin and the anti-CCR4 antibody, mogamuli

65 h is under way to extend the applications of brentuximab vedotin and to advance the field by developi

66 e two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastuzumab emtansine) and the f

67 020, a total of 13 patients with SS received brentuximab vedotin and were analyzed as part of a retro

68 Finally, brentuximab-vedotin and the KIT D816V-targeting drug PKC

69 4 women; median age, 46 years) responded to brentuximab vedotin, and 7 exhibited a complete response

70 (cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin, and etoposide) followed by brentuxi

71 ta were consistent with the known profile of brentuximab vedotin, and included at least grade 3 event

72 ither relapsed after or failed to respond to brentuximab vedotin, and with an Eastern Cooperative Onc

73 ience of the German Hodgkin Study Group with brentuximab vedotin as single agent in 45 patients with

74 Patients received brentuximab vedotin at 1.8 mg/kg (dose cap at 180 mg) an

75 enter dose-escalation study, we administered brentuximab vedotin (at a dose of 0.1 to 3.6 mg per kilo

76 med to understand the activity and safety of brentuximab vedotin-AVD in people living with HIV diagno

77 Brentuximab vedotin-AVD was highly active and had a tole

78 Brentuximab vedotin before reduced-intensity allo-HCT do

79 omography (PET)-adapted salvage therapy with brentuximab vedotin (BV) and augmented ifosfamide, carbo

80 ot study assessed the safety and efficacy of brentuximab vedotin (BV) and AVD (adriamycin, vinblastin

81 al cohorts, patients received four cycles of brentuximab vedotin (BV) and doxorubicin, vinblastine, a

82 In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administer

83 We present the efficacy and safety of brentuximab vedotin (BV) and nivolumab in combination wi

84 on of targeted immunotherapies specifically, brentuximab vedotin (BV) and programmed death-1 (PD-1)-b

85 The CD30-targeted, antibody-drug conjugate brentuximab vedotin (BV) and the immunomodulator lenalid

86 y over the past decade after the approval of brentuximab vedotin (BV) and the programmed death-1 (PD-

87 ) lymphomas have improved with the advent of brentuximab vedotin (BV) and, in Hodgkin lymphoma, anti-

88 This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo)

89 esponse-adapted approach with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustin

90 treatment with the anti-CD30 toxin conjugate brentuximab vedotin (BV) have been associated with remis

91 The improved outcomes with brentuximab vedotin (BV) in combination with cyclophosph

92 fficacy of the antibody-drug conjugate (ADC) brentuximab vedotin (BV) in relapsed/refractory peripher

93 Brentuximab vedotin (BV) is an antibody-drug conjugate t

94 2, nonrandomized, open-label study evaluated brentuximab vedotin (BV) monotherapy (results previously

95 The addition of brentuximab vedotin (BV) to a multidrug chemotherapy bac

96 med death-1 immune checkpoint inhibitor, and brentuximab vedotin (BV), an anti-CD30 antibody-drug con

97 V) cHL to six cycles of nivolumab (N)-AVD or brentuximab vedotin (BV)-AVD.

98 nventional chemotherapy to receive frontline brentuximab vedotin (BV; 1.8 mg/kg) with dacarbazine (DT

99 nts received doses of 0.6, 0.9, or 1.2 mg/kg brentuximab vedotin by intravenous infusion every 2 week

100 ory Committee for an accelerated approval of brentuximab vedotin by the Food and Drug Administration.

101 ficant proportion of patients who respond to brentuximab vedotin can achieve prolonged disease contro

102 or lines of therapy (range, 2-23), including brentuximab vedotin, checkpoint inhibitors, and autologo

103 s seem to be similar to previously presented brentuximab vedotin chemotherapy salvage combinations de

104 ractory Hodgkin lymphoma who were treated on brentuximab vedotin clinical trials to evaluate the effi

105 1.2 mg/kg brentuximab vedotin combined with AVD given every 2 week

106 ablish the safety and activity of dose-dense brentuximab vedotin combined with ifosfamide, carboplati

107 lerated dose and dose limiting toxicities of brentuximab vedotin combined with ipilimumab (ipilimumab

108 a, the CD30-directed antibody-drug conjugate brentuximab vedotin combined with multiagent chemotherap

109 We recorded consistent benefit (HR <1) of brentuximab vedotin consolidation across subgroups.

110 who responded to the treatment could receive brentuximab vedotin consolidation for up to ten addition

111 ntuximab vedotin, and etoposide) followed by brentuximab vedotin consolidation in patients with CD30-

112 with or without autologous HSCT) followed by brentuximab vedotin consolidation was safe and active.

113 tiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and

114 In vitro treatment with brentuximab vedotin decreased cell proliferation, induce

115 The antibody-drug conjugate brentuximab vedotin delivers the potent antimicrotubule

116 In phase I studies, brentuximab vedotin demonstrated significant activity wi

117 Brentuximab vedotin demonstrated significant clinical ac

118 Brentuximab vedotin demonstrated the most potent single

119 Brentuximab vedotin dose reduction to 1.2 mg/kg was perm

120 Recent data on combining brentuximab vedotin, doxorubicin, vinblastine, and dacar

121 the safety and efficacy of front-line A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacar

122 le ongoing clinical trials are investigating brentuximab vedotin efficacy in other CD30-positive hema

123 BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxoru

124 aphy (PET)-guided therapy with 4-6 cycles of brentuximab vedotin, etoposide, cyclophosphamide, doxoru

125 With the new regimen of brentuximab vedotin, etoposide, cyclophosphamide, doxoru

126 Brentuximab vedotin, first in class and gold standard, w

127 PET-adapted sequential salvage therapy with brentuximab vedotin followed by augICE resulted in a hig

128 -negative after brentuximab vedotin alone or brentuximab vedotin followed by augICE.

129 activity of PET-adapted salvage therapy with brentuximab vedotin, followed by augmented ifosfamide, c

130 el, single-center, phase 2 clinical trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas

131 ry approval of ado-trastuzumab emtansine and brentuximab vedotin for clinical use.

132 Responders received single-agent brentuximab vedotin for eight to 10 additional cycles (f

133 ical activity of the recently approved ADCs, brentuximab vedotin for Hodgkin lymphoma and ado-trastuz

134 TE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory classical

135 ese results support the potential utility of brentuximab vedotin for selected patients with HL relaps

136 To assess the efficacy and safety of brentuximab vedotin for the treatment of LyP.

137 rface antigens have been approved, including brentuximab vedotin, for the treatment of CD30-positive

138 12, we randomly assigned 329 patients to the brentuximab vedotin group (n=165) or the placebo group (

139 y was seen in 44 (67%) of 66 patients in the brentuximab vedotin group (n=21 grade 2, n=6 grade 3) an

140 e reported in 27 (41%) of 66 patients in the brentuximab vedotin group and 29 (47%) of 62 patients in

141 ears was 99.3% (95% CI, 97.3 to 99.8) in the brentuximab vedotin group and 98.5% (95% CI, 96.0 to 99.

142 apy did not differ substantially between the brentuximab vedotin group and the standard-care group (5

143 onths (95% CI 30.4-42.9) for patients in the brentuximab vedotin group compared with 24.1 months (11.

144 is, 28 (17%) of 167 patients had died in the brentuximab vedotin group compared with 25 (16%) of 160

145 as significantly improved in patients in the brentuximab vedotin group compared with those in the pla

146 The most frequent adverse events in the brentuximab vedotin group were peripheral sensory neurop

147 etoposide, prednisone, and cyclophosphamide (brentuximab vedotin group) or the standard pediatric reg

148 mab group vs one [1%] of 152 patients in the brentuximab vedotin group), neutropenia (three [2%] vs 1

149 nfidence interval [CI], 88.4 to 94.7) in the brentuximab vedotin group, as compared with 82.5% (95% C

150 investigator to be treatment-related in the brentuximab vedotin group; no on-treatment deaths were r

151 Brentuximab vedotin has been evaluated as a bridge to al

152 Although brentuximab vedotin has demonstrated excellent activity

153 The development of brentuximab vedotin has opened a new era in the manageme

154 Brentuximab vedotin has safely been combined with chemot

155 Brentuximab vedotin has shown significant clinical activ

156 t: pralatrexate, romidepsin, belinostat, and brentuximab vedotin have been approved for relapsed and

157 embrolizumab versus 8.3 months (5.7-8.8) for brentuximab vedotin (hazard ratio 0.65 [95% CI 0.48-0.88

158 We aimed to assess whether brentuximab vedotin improves progression-free survival w

159 , and the proposed phase 2 dose of 1.8 mg/kg brentuximab vedotin in CHEP-BV was confirmed.

160 (to confirm the recommended phase 2 dose of brentuximab vedotin in CHEP-BV) and the complete respons

161 ng preclinical indications for evaluation of brentuximab vedotin in clinical studies of PEL patients.

162 stablish the maximum tolerated dose (MTD) of brentuximab vedotin in combination with ABVD and AVD.

163 Brentuximab vedotin in combination with doxorubicin, vin

164 abel, dose-escalation safety study comparing brentuximab vedotin in combination with standard (ABVD)

165 y reported excellent therapeutic efficacy of brentuximab vedotin in heavily pretreated CD30(+) malign

166 nt value of CD30 as a therapeutic target for brentuximab vedotin in ongoing successful clinical trial

167 l transplantation (HSCT), consolidation with brentuximab vedotin in patients with high-risk relapsed

168 ucted to evaluate the efficacy and safety of brentuximab vedotin in patients with relapsed or refract

169 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refract

170 dy results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory

171 phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory

172 The integration of brentuximab vedotin in the frontline treatment of pediat

173 are well aware of the incredible success of brentuximab vedotin in the treatment of patients with Ho

174 However, brentuximab vedotin increases the toxic effects of treat

175 Brentuximab vedotin induced durable objective responses

176 Brentuximab vedotin induced objective responses in the m

177 Brentuximab vedotin induces an overall response rate of

178 The CD30-targeting antibody-conjugate brentuximab-vedotin inhibited proliferation in neoplasti

179 Incorporation of brentuximab vedotin into initial therapy for people with

180 Incorporating brentuximab vedotin into the treatment of advanced-stage

181 incristine 1.4 mg/m(2) and a placebo form of brentuximab vedotin intravenously (CHOP group) on day 1

182 one dose of either 1.2 mg/kg or 1.8 mg/kg of brentuximab vedotin intravenously on day 1 of a 21 day c

183 six planned cycles of CHEP-BV (ie, 1.8 mg/kg brentuximab vedotin intravenously on day 1, cyclophospha

184 Brentuximab vedotin is a CD30-directed antibody-drug con

185 Brentuximab vedotin is a monomethyl auristatin E-conjuga

186 The antibody drug conjugate brentuximab vedotin is a new, highly effective therapeut

187 Brentuximab vedotin is an anti-CD30 antibody-drug conjug

188 Brentuximab vedotin is an antibody-drug conjugate (ADC)

189 significant clinical efficacy, single-agent brentuximab vedotin is an approved treatment for relapse

190 Brentuximab vedotin is an effective treatment of relapse

191 The antibody drug conjugate brentuximab vedotin is associated with a high response r

192 Brentuximab vedotin is both active and well tolerated in

193 Brentuximab vedotin is currently approved for patients w

194 Brentuximab vedotin is effective in treating LyP (overal

195 Brentuximab vedotin is highly active in relapsed HL and

196 The CD30-specific antibody-drug conjugate, brentuximab vedotin, is approved for the treatment of re

197 Patients received 1.2 or 1.8 mg/kg of brentuximab vedotin IV every 3 weeks (median, 8 cycles;

198 ut according to institutional standards, and brentuximab vedotin maintenance was allowed following HD

199 diation, and 13 (33%) received post-HDT/AHCT brentuximab vedotin maintenance.

200 mic ALCL, provide evidence that single-agent brentuximab vedotin may be a potentially curative treatm

201 Brentuximab vedotin may offer a manageable treatment sch

202 results demonstrate for the first time that brentuximab vedotin may serve as an effective therapy fo

203 Brentuximab vedotin monotherapy may provide a frontline

204 Patients received a lead-in cycle of brentuximab vedotin monotherapy on days 1 and 15, follow

205 nts who achieved a complete response (CR) to brentuximab vedotin (N = 34) had estimated OS and PFS ra

206 ients received weekly infusions of 1.2 mg/kg brentuximab vedotin on days 1, 8, and 15 for two 28 day

207 % CI 60-86) patients were PET-positive after brentuximab vedotin; one PET-positive patient withdrew c

208 most of whom had previous exposure to either brentuximab vedotin or PD-1 blockade.

209 sequence, to receive 16 cycles of 1.8 mg/kg brentuximab vedotin or placebo intravenously every 3 wee

210 eceived any new treatment after single-agent brentuximab vedotin other than consolidative SCT.

211 showed no substantial age-related changes in brentuximab vedotin pharmacokinetics.

212 (7%) patients and diffuse rash at 1.2 mg/kg brentuximab vedotin plus 70 mg/m(2) of bendamustine in o

213 , including grade 4 neutropenia at 1.8 mg/kg brentuximab vedotin plus 80 mg/m(2) of bendamustine in t

214 is ongoing and will formally assess whether brentuximab vedotin plus AVD might redefine therapy in t

215 At present, a phase 3 trial comparing brentuximab vedotin plus AVD to ABVD alone is ongoing an

216 ed pulmonary toxic effects when treated with brentuximab vedotin plus AVD.

217 ase 2, all patients were assigned to receive brentuximab vedotin plus bendamustine at the recommended

218 and clinical activity of the combination of brentuximab vedotin plus bendamustine in heavily pretrea

219 INTERPRETATION: This study shows that brentuximab vedotin plus bendamustine, with a favourable

220 The ECHELON-2 study demonstrated that brentuximab vedotin plus cyclophosphamide, doxorubicin,

221 isone (CHOEP) for CD30-negative diseases, or brentuximab vedotin plus cyclophosphamide, doxorubicin,

222 Patients initiated brentuximab vedotin plus nivolumab for a median of 54 da

223 Brentuximab vedotin plus nivolumab is a safe and effecti

224 not meet the prespecified activity criteria, brentuximab vedotin plus nivolumab is active in older pa

225 Brentuximab vedotin plus nivolumab was highly active pos

226 ts were male, 29 (49%) completed 8 cycles of brentuximab vedotin plus nivolumab, and 45 (76%) complet

227 The addition of brentuximab vedotin prevented relapses during therapy, a

228 Moreover, brentuximab-vedotin produced apoptosis in all CD30(+) MC

229 Furthermore, in vivo brentuximab vedotin promoted tumor regression and prolon

230 s with persistent abnormalities on PET after brentuximab vedotin received augICE; however, all patien

231 were treated intravenously with 1.2 mg/kg of brentuximab vedotin (recommended phase 2 dose) with stan

232 AFM13 was also active in brentuximab vedotin-refractory patients.

233 Brentuximab vedotin replaced each vincristine in the OEP

234 Brentuximab vedotin represents one such ADC that has rec

235 in, the objective response rate was 59% with brentuximab vedotin retreatment after A+CHP and 50% with

236 Brentuximab vedotin (SGN-35) is an anti-CD30 monoclonal

237 pivotal phase 3 ALCANZA (A Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician's Choice [

238 The CD30-targeting Ab-drug conjugate brentuximab vedotin (SGN-35) was recently approved for t

239 inker, producing the antibody-drug conjugate brentuximab vedotin (SGN-35).

240 Brentuximab vedotin should not be given with bleomycin i

241 In summary, brentuximab vedotin showed antitumor activity in patient

242 In addition, brentuximab-vedotin suppressed the engraftment of MCPV-1

243 ients who relapsed and subsequently received brentuximab vedotin, the objective response rate was 59%

244 SS and with B2 blood involvement at the time brentuximab vedotin therapy was initiated.

245 and thus may serve as potential targets for brentuximab vedotin therapy.

246 Overall, the addition of brentuximab vedotin to standard chemotherapy does not ad

247 The addition of brentuximab vedotin to standard chemotherapy resulted in

248 valuable tool in optimizing patient-specific brentuximab vedotin treatment regimens.

249 After completion of brentuximab vedotin treatment, patients received a PET s

250 a model ADC (Ab095-PZ) and a commercial ADC (brentuximab vedotin) under the MS-compatible conditions.

251 In this case series, brentuximab vedotin use was associated with some efficac

252 4 months was 56.3% (36 of 64 patients) with brentuximab vedotin versus 12.5% (eight of 64) with phys

253 We aimed to assess efficacy and safety of brentuximab vedotin versus conventional therapy for prev

254 onse lasting at least 4 months was seen with brentuximab vedotin versus physician's choice of methotr

255 The ADC brentuximab vedotin was associated with manageable toxic

256 verse events were infrequent with nivolumab; brentuximab vedotin was associated with more treatment d

257 Brentuximab vedotin was delivered on days 1 and 8 at eit

258 The recommended phase 2 dose of brentuximab vedotin was established to be 1.5 mg/kg.

259 Brentuximab vedotin was given on day 1 of each of the 6

260 Overall, significant activity with brentuximab vedotin was observed in relapsed/refractory

261 Brentuximab vedotin was well tolerated and associated wi

262 Furthermore, brentuximab-vedotin was found to downregulate anti-IgE-i

263 The extended use of brentuximab-vedotin was reported for CD30(+) nonanaplast

264 The maximum tolerated dose of brentuximab vedotin when combined with ABVD or AVD was n

265 s in the therapeutic antibody-drug conjugate brentuximab vedotin, which displays a heterogeneous drug

266 The use of new drugs such as brentuximab vedotin will hopefully further increase the

267 12P1 determined the toxicity and efficacy of brentuximab vedotin with chemotherapy in children with n

268 Patients were randomly assigned to receive brentuximab vedotin with doxorubicin, vinblastine, and d

269 re assigned to receive five 21-day cycles of brentuximab vedotin with doxorubicin, vincristine, etopo

270 Incorporating brentuximab vedotin with frontline regimens is currently

271 y activity for the two most active regimens, brentuximab vedotin with nivolumab and the triplet thera

272 d the safety and activity of combinations of brentuximab vedotin with nivolumab or ipilimumab, or bot

273 The combination of brentuximab vedotin with rituximab was generally well to

274 ts who achieved a complete remission (CR) on brentuximab vedotin, with estimated 3-year overall survi

275 t in progression-free survival compared with brentuximab vedotin, with safety consistent with previou